BAMS
ABUS icon

Bellevue Asset Management (Switzerland)’s Arbutus Biopharma ABUS Stock Holding History

Bellevue Asset Management (Switzerland)’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$556K Hold
125,000
– – 0.08% 113
2015
Q3 		$761K Hold
125,000
– – 0.12% 111
2015
Q2 		$1.48M Buy
+125,000
New +$1.9M 0.21% 103

Other funds holding ABUS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bellevue Asset Management (Switzerland)'s ABUS Position: Q4 2015 in Review

Bellevue Asset Management (Switzerland) held its Arbutus Biopharma (ABUS) position steady in Q4 2015 at 125,000 shares worth $556K. The position accounts for 0.08% of the portfolio, ranked #113.

Bellevue Asset Management (Switzerland) first reported a position in ABUS in Q2 2015 and has held it in 3 quarters since. The position peaked at $1.48M in Q2 2015. 51 funds tracked by Wall St. Rank hold ABUS as of Q4 2015.

  • Bellevue Asset Management (Switzerland) held 125,000 shares of Arbutus Biopharma worth $556K as of Q4 2015.
  • Bellevue Asset Management (Switzerland) left its Arbutus Biopharma share count unchanged in Q4 2015.
  • Arbutus Biopharma made up 0.08% of Bellevue Asset Management (Switzerland)'s portfolio in Q4 2015, its #113 holding.
  • Bellevue Asset Management (Switzerland) first reported a position in Arbutus Biopharma in Q2 2015 and has held it in 3 quarters since.
  • Bellevue Asset Management (Switzerland)'s Arbutus Biopharma position peaked at $1.48M in Q2 2015.
  • 51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q4 2015.

Based on Bellevue Asset Management (Switzerland)'s 13F filing for Q4 2015, filed 12 Feb 2016.